In the spleen, ibrutinib-treated mice with HUS showed a trend towards decreased NLRP3 (Figure 5C) and pro-IL-1β (Figure 5D) expression, while acalabrutinib-treated mice with HUS showed a significantly decreased protein expression of NLRP3 (Figure 5C) and pro-IL-1β (Figure 5D) compared with vehicle-treated mice with HUS. The gene discussed is NLRP3; the disease is hemolytic-uremic syndrome.